<?xml version="1.0" encoding="UTF-8"?>
<OAI-PMH xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd">
  <responseDate>2022-03-11T00:46:35Z</responseDate>
  <request verb="GetRecord" identifier="oai:pubmedcentral.nih.gov:8629270" metadataPrefix="pmc">https:/www.ncbi.nlm.nih.gov/pmc/oai/oai.cgi</request>
  <GetRecord>
    <record>
      <header>
        <identifier>oai:pubmedcentral.nih.gov:8629270</identifier>
        <datestamp>2021-11-30</datestamp>
        <setSpec>plosone</setSpec>
        <setSpec>pmc-open</setSpec>
      </header>
      <metadata>
        <article xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xsi:schemaLocation="https://jats.nlm.nih.gov/ns/archiving/1.3/ https://jats.nlm.nih.gov/archiving/1.3/xsd/JATS-archivearticle1-3.xsd" dtd-version="1.3" xml:lang="en" article-type="research-article">
          <processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats">
            <restricted-by>pmc</restricted-by>
          </processing-meta>
          <front>
            <journal-meta>
              <journal-id journal-id-type="nlm-ta">PLoS One</journal-id>
              <journal-id journal-id-type="iso-abbrev">PLoS One</journal-id>
              <journal-id journal-id-type="publisher-id">plos</journal-id>
              <journal-title-group>
                <journal-title>PLoS ONE</journal-title>
              </journal-title-group>
              <issn pub-type="epub">1932-6203</issn>
              <publisher>
                <publisher-name>Public Library of Science</publisher-name>
                <publisher-loc>San Francisco, CA USA</publisher-loc>
              </publisher>
            </journal-meta>
            <article-meta>
              <article-id pub-id-type="accession">PMC8629270</article-id>
              <article-id pub-id-type="pmcid">PMC8629270</article-id>
              <article-id pub-id-type="pmc-uid">8629270</article-id>
              <article-id pub-id-type="pmid">34843552</article-id>
              <article-id pub-id-type="doi">10.1371/journal.pone.0260364</article-id>
              <article-id pub-id-type="publisher-id">PONE-D-21-13349</article-id>
              <article-categories>
                <subj-group subj-group-type="heading">
                  <subject>Research Article</subject>
                </subj-group>
                <subj-group subj-group-type="Discipline-v3">
                  <subject>Medicine and Health Sciences</subject>
                  <subj-group>
                    <subject>Medical Conditions</subject>
                    <subj-group>
                      <subject>Infectious Diseases</subject>
                      <subj-group>
                        <subject>Viral Diseases</subject>
                        <subj-group>
                          <subject>Covid 19</subject>
                        </subj-group>
                      </subj-group>
                    </subj-group>
                  </subj-group>
                </subj-group>
                <subj-group subj-group-type="Discipline-v3">
                  <subject>Biology and Life Sciences</subject>
                  <subj-group>
                    <subject>Psychology</subject>
                    <subj-group>
                      <subject>Behavior</subject>
                      <subj-group>
                        <subject>Recreation</subject>
                      </subj-group>
                    </subj-group>
                  </subj-group>
                </subj-group>
                <subj-group subj-group-type="Discipline-v3">
                  <subject>Social Sciences</subject>
                  <subj-group>
                    <subject>Psychology</subject>
                    <subj-group>
                      <subject>Behavior</subject>
                      <subj-group>
                        <subject>Recreation</subject>
                      </subj-group>
                    </subj-group>
                  </subj-group>
                </subj-group>
                <subj-group subj-group-type="Discipline-v3">
                  <subject>Medicine and Health Sciences</subject>
                  <subj-group>
                    <subject>Epidemiology</subject>
                    <subj-group>
                      <subject>Infectious Disease Epidemiology</subject>
                    </subj-group>
                  </subj-group>
                </subj-group>
                <subj-group subj-group-type="Discipline-v3">
                  <subject>Medicine and Health Sciences</subject>
                  <subj-group>
                    <subject>Medical Conditions</subject>
                    <subj-group>
                      <subject>Infectious Diseases</subject>
                      <subj-group>
                        <subject>Infectious Disease Epidemiology</subject>
                      </subj-group>
                    </subj-group>
                  </subj-group>
                </subj-group>
                <subj-group subj-group-type="Discipline-v3">
                  <subject>Medicine and Health Sciences</subject>
                  <subj-group>
                    <subject>Medical Conditions</subject>
                    <subj-group>
                      <subject>Infectious Diseases</subject>
                      <subj-group>
                        <subject>Respiratory Infections</subject>
                      </subj-group>
                    </subj-group>
                  </subj-group>
                </subj-group>
                <subj-group subj-group-type="Discipline-v3">
                  <subject>Medicine and Health Sciences</subject>
                  <subj-group>
                    <subject>Medical Conditions</subject>
                    <subj-group>
                      <subject>Respiratory Disorders</subject>
                      <subj-group>
                        <subject>Respiratory Infections</subject>
                      </subj-group>
                    </subj-group>
                  </subj-group>
                </subj-group>
                <subj-group subj-group-type="Discipline-v3">
                  <subject>Medicine and Health Sciences</subject>
                  <subj-group>
                    <subject>Pulmonology</subject>
                    <subj-group>
                      <subject>Respiratory Disorders</subject>
                      <subj-group>
                        <subject>Respiratory Infections</subject>
                      </subj-group>
                    </subj-group>
                  </subj-group>
                </subj-group>
                <subj-group subj-group-type="Discipline-v3">
                  <subject>Medicine and Health Sciences</subject>
                  <subj-group>
                    <subject>Epidemiology</subject>
                    <subj-group>
                      <subject>Pandemics</subject>
                    </subj-group>
                  </subj-group>
                </subj-group>
                <subj-group subj-group-type="Discipline-v3">
                  <subject>Medicine and Health Sciences</subject>
                  <subj-group>
                    <subject>Medical Conditions</subject>
                    <subj-group>
                      <subject>Infectious Diseases</subject>
                      <subj-group>
                        <subject>Infectious Disease Control</subject>
                        <subj-group>
                          <subject>Vaccines</subject>
                          <subj-group>
                            <subject>Viral Vaccines</subject>
                          </subj-group>
                        </subj-group>
                      </subj-group>
                    </subj-group>
                  </subj-group>
                </subj-group>
                <subj-group subj-group-type="Discipline-v3">
                  <subject>Biology and Life Sciences</subject>
                  <subj-group>
                    <subject>Microbiology</subject>
                    <subj-group>
                      <subject>Virology</subject>
                      <subj-group>
                        <subject>Viral Vaccines</subject>
                      </subj-group>
                    </subj-group>
                  </subj-group>
                </subj-group>
                <subj-group subj-group-type="Discipline-v3">
                  <subject>Research and Analysis Methods</subject>
                  <subj-group>
                    <subject>Simulation and Modeling</subject>
                  </subj-group>
                </subj-group>
                <subj-group subj-group-type="Discipline-v3">
                  <subject>Medicine and Health Sciences</subject>
                  <subj-group>
                    <subject>Epidemiology</subject>
                  </subj-group>
                </subj-group>
              </article-categories>
              <title-group>
                <article-title>The effectiveness of Non-pharmaceutical interventions in reducing the COVID-19 contagion in the UK, an observational and modelling study</article-title>
                <alt-title alt-title-type="running-head">The effectiveness of Non-pharmaceutical interventions in reducing the COVID-19 contagion in the UK</alt-title>
              </title-group>
              <contrib-group>
                <contrib contrib-type="author" equal-contrib="yes">
                  <name>
                    <surname>Galanis</surname>
                    <given-names>Giorgos</given-names>
                  </name>
                  <role content-type="http://credit.niso.org/contributor-roles/writing-original-draft/">Writing – original draft</role>
                  <xref rid="aff001" ref-type="aff">
                    <sup>1</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Di Guilmi</surname>
                    <given-names>Corrado</given-names>
                  </name>
                  <role content-type="http://credit.niso.org/contributor-roles/writing-review-editing/">Writing – review &amp; editing</role>
                  <xref rid="aff002" ref-type="aff">
                    <sup>2</sup>
                  </xref>
                  <xref rid="econtrib001" ref-type="author-notes">
                    <sup>‡</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Bennett</surname>
                    <given-names>David L.</given-names>
                  </name>
                  <role content-type="http://credit.niso.org/contributor-roles/writing-review-editing/">Writing – review &amp; editing</role>
                  <xref rid="aff003" ref-type="aff">
                    <sup>3</sup>
                  </xref>
                  <xref rid="econtrib001" ref-type="author-notes">
                    <sup>‡</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author" equal-contrib="yes">
                  <contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0001-9237-5878</contrib-id>
                  <name>
                    <surname>Baskozos</surname>
                    <given-names>Georgios</given-names>
                  </name>
                  <role content-type="http://credit.niso.org/contributor-roles/data-curation/">Data curation</role>
                  <role content-type="http://credit.niso.org/contributor-roles/writing-original-draft/">Writing – original draft</role>
                  <xref rid="aff003" ref-type="aff">
                    <sup>3</sup>
                  </xref>
                  <xref rid="cor001" ref-type="corresp">*</xref>
                </contrib>
              </contrib-group>
              <aff id="aff001">
                <label>1</label>
                <addr-line>Institute of Management Studies, Goldsmiths, University of London, London, United Kingdom</addr-line>
              </aff>
              <aff id="aff002">
                <label>2</label>
                <addr-line>Department of Economics, University of Technology Sydney, Sydney, Australia</addr-line>
              </aff>
              <aff id="aff003">
                <label>3</label>
                <addr-line>Neural Injury Group, Nuffield Department of Clinical Neuroscience, John Radcliffe Hospital, University of Oxford, Oxford, United Kingdom</addr-line>
              </aff>
              <contrib-group>
                <contrib contrib-type="editor">
                  <name>
                    <surname>Mitra</surname>
                    <given-names>Prasenjit</given-names>
                  </name>
                  <role>Editor</role>
                  <xref rid="edit1" ref-type="aff"/>
                </contrib>
              </contrib-group>
              <aff id="edit1">
                <addr-line>Post Graduate Institute of Medical Education and Research, INDIA</addr-line>
              </aff>
              <author-notes>
                <fn fn-type="COI-statement" id="coi001">
                  <p><bold>Competing Interests: </bold>The authors have declared that no competing interests exist.</p>
                </fn>
                <fn fn-type="other" id="econtrib001">
                  <p>‡ CDG and DLB also contributed equally to this work</p>
                </fn>
                <corresp id="cor001">* E-mail: <email>georgios.baskozos@ndcn.ox.ac.uk</email></corresp>
              </author-notes>
              <pub-date pub-type="epub">
                <day>29</day>
                <month>11</month>
                <year>2021</year>
              </pub-date>
              <pub-date pub-type="collection">
                <year>2021</year>
              </pub-date>
              <pub-date pub-type="pmc-release">
                <day>29</day>
                <month>11</month>
                <year>2021</year>
              </pub-date>
              <!--PMC Release delay is 0 months and 0 days and was based on the <pub-date pub-type="epub"/>.-->
              <volume>16</volume>
              <issue>11</issue>
              <elocation-id>e0260364</elocation-id>
              <history>
                <date date-type="received">
                  <day>22</day>
                  <month>4</month>
                  <year>2021</year>
                </date>
                <date date-type="accepted">
                  <day>8</day>
                  <month>11</month>
                  <year>2021</year>
                </date>
              </history>
              <permissions>
                <copyright-statement>© 2021 Galanis et al</copyright-statement>
                <copyright-year>2021</copyright-year>
                <copyright-holder>Galanis et al</copyright-holder>
                <license>
                  <ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref>
                  <license-p>This is an open access article distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.</license-p>
                </license>
              </permissions>
              <self-uri content-type="pdf" xlink:href="pone.0260364.pdf"/>
              <abstract>
                <p>Epidemiological models used to inform government policies aimed to reduce the contagion of COVID-19, assume that the reproduction number is reduced through Non-Pharmaceutical Interventions (NPIs) leading to physical distancing. Available data in the UK show an increase in physical distancing before the NPIs were implemented and a fall soon after implementation. We aimed to estimate the effect of people’s behaviour on the epidemic curve and the effect of NPIs taking into account this behavioural component. We have estimated the effects of confirmed daily cases on physical distancing and we used this insight to design a behavioural SEIR model (BeSEIR), simulated different scenaria regarding NPIs and compared the results to the standard SEIR. Taking into account behavioural insights improves the description of the contagion dynamics of the epidemic significantly. The BeSEIR predictions regarding the number of infections without NPIs were several orders of magnitude less than the SEIR. However, the BeSEIR prediction showed that early measures would still have an important influence in the reduction of infections. The BeSEIR model shows that even with no intervention the percentage of the cumulative infections within a year will not be enough for the epidemic to resolve due to a herd immunity effect. On the other hand, a standard SEIR model significantly overestimates the effectiveness of measures. Without taking into account the behavioural component, the epidemic is predicted to be resolved much sooner than when taking it into account and the effectiveness of measures are significantly overestimated.</p>
              </abstract>
              <funding-group>
                <award-group id="award001">
                  <funding-source>
                    <institution-wrap>
                      <institution-id institution-id-type="funder-id">http://dx.doi.org/10.13039/100004440</institution-id>
                      <institution>Wellcome Trust</institution>
                    </institution-wrap>
                  </funding-source>
                  <award-id>202747/Z/16/Z</award-id>
                  <principal-award-recipient>
                    <name>
                      <surname>Bennett</surname>
                      <given-names>David L.</given-names>
                    </name>
                  </principal-award-recipient>
                </award-group>
                <award-group id="award002">
                  <funding-source>
                    <institution>Diabetes UK</institution>
                  </funding-source>
                  <award-id>19/0005984</award-id>
                  <principal-award-recipient>
                    <contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0001-9237-5878</contrib-id>
                    <name>
                      <surname>Baskozos</surname>
                      <given-names>Georgios</given-names>
                    </name>
                  </principal-award-recipient>
                </award-group>
                <award-group id="award003">
                  <funding-source>
                    <institution>Diabetes UK</institution>
                  </funding-source>
                  <award-id>19/0005984</award-id>
                  <principal-award-recipient>
                    <name>
                      <surname>Bennett</surname>
                      <given-names>David L.</given-names>
                    </name>
                  </principal-award-recipient>
                </award-group>
                <funding-statement>D.L.B has acted as a consultant on behalf of Oxford Innovation in the last 2 years for Amgen, CODA therapeutic, Bristows, Lilly, Mundipharma and Theranexus. D.L.B has an MRC Industrial Partnership grant with Astra Zeneca. D.L.B is a senior Wellcome clinical scientist (202747/Z/16/Z). G.B and D.L.B are funded by Diabetes UK (19/0005984). Sponsor’s had no role in study design, in the collection, analysis and interpretation of data; in the writing of the article; and in the decision to submit it for pub-lication.</funding-statement>
              </funding-group>
              <counts>
                <fig-count count="5"/>
                <table-count count="0"/>
                <page-count count="13"/>
              </counts>
              <custom-meta-group>
                <custom-meta id="data-availability">
                  <meta-name>Data Availability</meta-name>
                  <meta-value>All data is publicly available from <ext-link xlink:href="https://covid19.who.int/?gclid=CjwKCAjwltH3BRB6EiwAhj0IUD_ZYpmWYI5f1P9OYsYlJKTajlyFvk5aXAwQNMNIoL82XsVMfF4LExoC8e4QAvD_BwE" ext-link-type="uri">https://covid19.who.int/?gclid=CjwKCAjwltH3BRB6EiwAhj0IUD_ZYpmWYI5f1P9OYsYlJKTajlyFvk5aXAwQNMNIoL82XsVMfF4LExoC8e4QAvD_BwE</ext-link>
<ext-link xlink:href="https://www.gov.uk/government/collections/national-travel-survey-statistics" ext-link-type="uri">https://www.gov.uk/government/collections/national-travel-survey-statistics</ext-link> and <ext-link xlink:href="https://www.google.com/covid19/mobility?hl=en" ext-link-type="uri">https://www.google.com/covid19/mobility?hl=en</ext-link>.</meta-value>
                </custom-meta>
                <custom-meta id="outbreaks">
                  <meta-name>Outbreaks</meta-name>
                  <meta-value>COVID-19</meta-value>
                </custom-meta>
              </custom-meta-group>
            </article-meta>
            <notes>
              <title>Data Availability</title>
              <p>All data is publicly available from <ext-link xlink:href="https://covid19.who.int/?gclid=CjwKCAjwltH3BRB6EiwAhj0IUD_ZYpmWYI5f1P9OYsYlJKTajlyFvk5aXAwQNMNIoL82XsVMfF4LExoC8e4QAvD_BwE" ext-link-type="uri">https://covid19.who.int/?gclid=CjwKCAjwltH3BRB6EiwAhj0IUD_ZYpmWYI5f1P9OYsYlJKTajlyFvk5aXAwQNMNIoL82XsVMfF4LExoC8e4QAvD_BwE</ext-link>
<ext-link xlink:href="https://www.gov.uk/government/collections/national-travel-survey-statistics" ext-link-type="uri">https://www.gov.uk/government/collections/national-travel-survey-statistics</ext-link> and <ext-link xlink:href="https://www.google.com/covid19/mobility?hl=en" ext-link-type="uri">https://www.google.com/covid19/mobility?hl=en</ext-link>.</p>
            </notes>
          </front>
          <body>
            <sec sec-type="intro" id="sec001">
              <title>Introduction</title>
              <p>The spread of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus responsible for COVID-19 has led to more than 9,277,214 confirmed cases and more than 3,032,124 deaths as of 21/04/2021 [<xref rid="pone.0260364.ref001" ref-type="bibr">1</xref>]. Apart from the health-related implications, COVID-19 has been affecting almost every aspect of people’s lives and these effects have been unequally distributed [<xref rid="pone.0260364.ref002" ref-type="bibr">2</xref>].</p>
              <p>Governments have resorted to health policies known as Non-Pharmaceutical Interventions (NPIs), aimed to reduce the average number of contacts between individuals (physical distancing). While during the first period of the pandemic where no vaccines had been available, NPIs had been the only available measure in reducing the spread of the virus, since a number of vaccines became available in a number of countries, NPIs are being used in parallel to vaccination [<xref rid="pone.0260364.ref003" ref-type="bibr">3</xref>–<xref rid="pone.0260364.ref005" ref-type="bibr">5</xref>].</p>
              <p>A number of studies have explored the effects of NPIs on the contagion dynamics of COVID-19. [<xref rid="pone.0260364.ref006" ref-type="bibr">6</xref>–<xref rid="pone.0260364.ref011" ref-type="bibr">11</xref>]. One of the focuses of relevant models is the estimation of the effects of NPIs on the rate of spread of the epidemic, captured by the reproduction number, which differs across countries [<xref rid="pone.0260364.ref012" ref-type="bibr">12</xref>] and this can be due to a number of social and economic conditions [<xref rid="pone.0260364.ref013" ref-type="bibr">13</xref>, <xref rid="pone.0260364.ref014" ref-type="bibr">14</xref>]. Hence, the effectiveness of the different policies depends on how the various measures reduce this parameter. In order to be able to capture the level of this effect, it is necessary to estimate the value of the reproduction number, which in standard compartmental models is assumed to be initially close to constant and changes as a response to active NPIs [<xref rid="pone.0260364.ref012" ref-type="bibr">12</xref>].</p>
              <p>However, data which capture mobility levels of individuals show that in a number of countries, including the UK, people took physical distancing measures before governments imposed NPIs. This behaviour, fits well with the insights of models, which take into account behavioural changes over and above NPIs [<xref rid="pone.0260364.ref006" ref-type="bibr">6</xref>, <xref rid="pone.0260364.ref015" ref-type="bibr">15</xref>] such that the effective reproduction number becomes (at least partly) endogenous. Nonetheless, these works are theoretical and have not been applied to data sets related to COVID-19 so far.</p>
              <p>The purpose of our study was threefold: (i) assess the influence of NPIs on physical distancing in the UK, taking explicitly into account the physical distancing behaviour due to observed cases; (ii) extend the standard SEIR model in order to incorporate individuals’ physical distancing behaviour using the analysis from (i); and (iii) use this extended model to study the effectiveness of the NPIs, including the level and timing of NPIs imposed and the possible effects of lifting the relevant measures.</p>
            </sec>
            <sec sec-type="materials|methods" id="sec002">
              <title>Methods</title>
              <sec id="sec003">
                <title>Data and statistical analysis</title>
                <p>In order to assess the influence of both NPIs and the observed information, we analysed the correlation between individuals’ mobility levels and the number of daily confirmed cases of the previous day as reported in the WHO dashboard [<xref rid="pone.0260364.ref001" ref-type="bibr">1</xref>] for three different periods: (a) up to the point when physical distancing advice was given (b) between this advice and enforceable lockdown, and (c) after lockdown. Enforceable lockdown includes NPIs ranging from the closure of public spaces, transportation hubs and shops to forbidding interactions with people outside one’s household and ban any unnecessary travel. Following Buckee et al. (2020) [<xref rid="pone.0260364.ref016" ref-type="bibr">16</xref>], we created an aggregated data time series for physical distancing in the UK using data from Google’s “COVID-19 Community Mobility Reports” [<xref rid="pone.0260364.ref017" ref-type="bibr">17</xref>]. Data in Google’s Community Mobility Reports has undergone differential anonymisation and does not contain any personally identifiable information. Data are generated by aggregation people that have turned on their "location history" setting. Data points are expressed as percentage differences from baseline and validated to be in the expected range of –100 to 100.</p>
                <p>Data shows the changes in mobility in six different categories:</p>
                <list list-type="order">
                  <list-item>
                    <p><italic toggle="yes">Retail and recreation</italic>, reporting the mobility trends for places such as restaurants, shopping centres, libraries and cinemas.</p>
                  </list-item>
                  <list-item>
                    <p><italic toggle="yes">Supermarket and pharmacy</italic>, capturing the trends for places such as supermarkets, food warehouses and pharmacies</p>
                  </list-item>
                  <list-item>
                    <p><italic toggle="yes">Parks</italic>, which shows the mobility trends for places like parks, public beaches, plazas and public gardens.</p>
                  </list-item>
                  <list-item>
                    <p><italic toggle="yes">Public transport</italic>, which shows the mobility trends for places that are public transport hubs, such as underground, bus and train stations.</p>
                  </list-item>
                  <list-item>
                    <p><italic toggle="yes">Workplaces</italic>, capturing mobility trends to places of work</p>
                  </list-item>
                  <list-item>
                    <p><italic toggle="yes">Residential</italic>, which shows mobility trends for places of residence.</p>
                  </list-item>
                </list>
                <p>We noted that not all of the above categories are relevant for measuring levels of physical distancing, which on one hand are related to both NPIs and to individuals’ behaviour, while on the other are relevant for the contagion dynamics. For this reason, we used the categories “Workplaces”, “Public transport”, “Retail and recreation”. We defined as mobility <italic toggle="yes">m</italic><sub><italic toggle="yes">t</italic></sub> at time <italic toggle="yes">t</italic>, a weighted average of these three categories. In order to calculate the different weights, we first matched these categories with the relevant ones from the national travel survey, 2018 [<xref rid="pone.0260364.ref018" ref-type="bibr">18</xref>] which includes the following travel categories: Business, Education, Escort education, Shopping, Personal Business, Visiting friends at private home, Visiting friends elsewhere, Entertainment / public activity, Sport, Holiday, Day trip, Other.</p>
                <p>We matched the National Travel Survey categories “Holiday”, “Day trip”, “Entertainment / public activity”, “Shopping”, “Visiting friends elsewhere (than home)” to the “Retail and Recreation” mobility trend; “Commuting”, “Business” and “Personal Business” to the “Workplaces” mobility trend. Additionally, we hypothesised that the “Public Transport / Transit” mobility trend uniformly influences both the above trends. We then computed the relative weights of the above activities with regards to the total activities and mapped these weights to the three mobility categories. This gave us relative weights of 0.38 for “Retail and Recreation”, 0.29 for “Workplaces” and 0.33 for “Public Transport/Transit”. We observe that mobility over time resembles a logistic distribution and the same is true for new confirmed cases (<italic toggle="yes">c</italic><sub><italic toggle="yes">t</italic></sub>), (<xref rid="pone.0260364.g001" ref-type="fig">Fig 1</xref>).</p>
                <fig position="float" id="pone.0260364.g001">
                  <object-id pub-id-type="doi">10.1371/journal.pone.0260364.g001</object-id>
                  <label>Fig 1</label>
                  <caption>
                    <title>Mobility and new confirmed cases for the UK 15-02-2020: 14-06-2020.</title>
                  </caption>
                  <graphic xlink:href="pone.0260364.g001" position="float"/>
                </fig>
                <p>The gold line represents the 7-day rolling mean of the new confirmed cases per day. Values are scaled to the range of 0–100. The green line represents the weighted average of the percentage drop of mobility trends from baseline. Vertical dashed lines show the timing of various Non-Pharmaceutical Interventions. Mobility data has been downloaded from google mobility trends and is publicly available, [<xref rid="pone.0260364.ref017" ref-type="bibr">17</xref>] new daily cases has been downloaded from the WHO dashboard [<xref rid="pone.0260364.ref001" ref-type="bibr">1</xref>] and is publicly available.</p>
                <p>We observed two periods: one with a sharp decrease in mobility and one with a slight increase. The plots of the confirmed cases follow a very similar pattern but in opposite directions. The different NPIs seem to have an effect of the slope of both lines. The fall in confirmed cases happens around 14 days after the NPIs have been introduced and a big fall in mobility has taken place.</p>
                <p>Based on this observation, it is reasonable to assume that there is a linear relationship between the two data series and that the available information in one period affects the decision for the next, which means that <italic toggle="yes">m</italic><sub><italic toggle="yes">t</italic></sub> is a linear function of <italic toggle="yes">c</italic><sub><italic toggle="yes">t</italic>-1</sub> ie.
<disp-formula id="pone.0260364.e001"><alternatives><graphic xlink:href="pone.0260364.e001.jpg" id="pone.0260364.e001g" position="anchor"/><mml:math id="M1" display="block" overflow="scroll"><mml:mrow><mml:msub><mml:mi>m</mml:mi><mml:mi>t</mml:mi></mml:msub><mml:mo>=</mml:mo><mml:msub><mml:mi>λ</mml:mi><mml:mn>0</mml:mn></mml:msub><mml:msub><mml:mi>c</mml:mi><mml:mrow><mml:mi>t</mml:mi><mml:mo>−</mml:mo><mml:mn>1</mml:mn></mml:mrow></mml:msub><mml:mo>+</mml:mo><mml:msub><mml:mi>λ</mml:mi><mml:mn>1</mml:mn></mml:msub><mml:mo>,</mml:mo></mml:mrow></mml:math></alternatives></disp-formula>
where <italic toggle="yes">λ</italic><sub>0</sub> captures the effect of daily confirmed cases and <italic toggle="yes">λ</italic><sub>1</sub> other influences including the effects of NPIs.</p>
                <p>However, given that also NPIs affect mobility, we tested this hypothesis for three different periods: before advice, between advice and lockdown, and after lockdown. This hypothesis is supported by very high and significant correlation between the two variables in all three different periods (<xref rid="pone.0260364.s001" ref-type="supplementary-material">S1 Fig</xref>).</p>
                <p>This observation highlights the fact that NPIs are not the only factors which influence mobility which in turn is related to physical distancing levels and the reproduction number of COVID-19. Behaviour should therefore be taken into account in relevant models and policy simulations.</p>
              </sec>
              <sec id="sec004">
                <title>Behavioural SEIR Model</title>
                <p>The key variable informing NPIs is the reproduction number, which is the fraction of the transmission rate of the epidemic (<italic toggle="yes">β</italic><sub><italic toggle="yes">t</italic></sub>) over the recovery rate of infected individuals (γ). The daily transmission rate (and hence the basic or effective reproduction number) directly depends on the number contacts per individual, which means that due to the assumption that mobility is a proxy of daily number of contacts we can express <italic toggle="yes">β</italic><sub><italic toggle="yes">t</italic></sub> as
<disp-formula id="pone.0260364.e002"><alternatives><graphic xlink:href="pone.0260364.e002.jpg" id="pone.0260364.e002g" position="anchor"/><mml:math id="M2" display="block" overflow="scroll"><mml:mrow><mml:msub><mml:mi>β</mml:mi><mml:mi>t</mml:mi></mml:msub><mml:mo>=</mml:mo><mml:mi>P</mml:mi><mml:msub><mml:mi>m</mml:mi><mml:mi>t</mml:mi></mml:msub><mml:mo>=</mml:mo><mml:mi>ζ</mml:mi><mml:msub><mml:mi>c</mml:mi><mml:mrow><mml:mi>t</mml:mi><mml:mo>−</mml:mo><mml:mn>1</mml:mn></mml:mrow></mml:msub><mml:mo>+</mml:mo><mml:mi>ε</mml:mi></mml:mrow></mml:math></alternatives><label>(1)</label></disp-formula>
where <italic toggle="yes">P</italic> is the probability of getting infected if susceptible, <italic toggle="yes">m</italic><sub><italic toggle="yes">t</italic></sub> is the mobility as defined above <italic toggle="yes">ε</italic> = <italic toggle="yes">P</italic><italic toggle="yes">λ</italic><sub>0</sub> and <italic toggle="yes">ζ</italic> = <italic toggle="yes">P</italic><italic toggle="yes">λ</italic><sub>1</sub> capture the relative importance of the behavioural component related to observed infections and the NPIs respectively, such that for <italic toggle="yes">ζ</italic> = 0 only NPIs would affect the level of <italic toggle="yes">β</italic><sub><italic toggle="yes">t</italic></sub>. Note that <italic toggle="yes">ζ</italic> and <italic toggle="yes">ε</italic> are the slope and intercept of the linear model fitting the data as described in the previous section.</p>
                <p>We divided the population of individuals according to the infection status into susceptible (<italic toggle="yes">S</italic><sub><italic toggle="yes">t</italic></sub>), exposed (<italic toggle="yes">E</italic><sub><italic toggle="yes">t</italic></sub>), infected (<italic toggle="yes">I</italic><sub><italic toggle="yes">t</italic></sub>) and removed ones (<italic toggle="yes">R</italic><sub><italic toggle="yes">t</italic></sub>) such that
<disp-formula id="pone.0260364.e003"><alternatives><graphic xlink:href="pone.0260364.e003.jpg" id="pone.0260364.e003g" position="anchor"/><mml:math id="M3" display="block" overflow="scroll"><mml:mrow><mml:msub><mml:mi>S</mml:mi><mml:mi>t</mml:mi></mml:msub><mml:mo>+</mml:mo><mml:msub><mml:mi>E</mml:mi><mml:mi>t</mml:mi></mml:msub><mml:mo>+</mml:mo><mml:msub><mml:mi>I</mml:mi><mml:mi>t</mml:mi></mml:msub><mml:mo>+</mml:mo><mml:msub><mml:mi>R</mml:mi><mml:mi>t</mml:mi></mml:msub><mml:mo>=</mml:mo><mml:mi>N</mml:mi><mml:mtext>.</mml:mtext></mml:mrow></mml:math></alternatives><label>(2)</label></disp-formula></p>
                <p>Susceptible subjects might get infected when they contact an infectious individual and if infected, they enter the exposed compartment before the infected one. Following Prem et al. (2020) [<xref rid="pone.0260364.ref008" ref-type="bibr">8</xref>], the infected individuals are split into two further groups where the first group is symptomatic and clinical (<inline-formula id="pone.0260364.e004"><alternatives><graphic xlink:href="pone.0260364.e004.jpg" id="pone.0260364.e004g" position="anchor"/><mml:math id="M4" display="inline" overflow="scroll"><mml:mrow><mml:msubsup><mml:mi>I</mml:mi><mml:mi>t</mml:mi><mml:mi>C</mml:mi></mml:msubsup></mml:mrow></mml:math></alternatives></inline-formula>) and the second asymptomatic and subclinical (<inline-formula id="pone.0260364.e005"><alternatives><graphic xlink:href="pone.0260364.e005.jpg" id="pone.0260364.e005g" position="anchor"/><mml:math id="M5" display="inline" overflow="scroll"><mml:mrow><mml:msubsup><mml:mi>I</mml:mi><mml:mi>t</mml:mi><mml:mrow><mml:mi>S</mml:mi><mml:mi>C</mml:mi></mml:mrow></mml:msubsup></mml:mrow></mml:math></alternatives></inline-formula>). The first group is a fraction <italic toggle="yes">ρ</italic> of the total infected and the second is 1 - <italic toggle="yes">ρ</italic> of the total.</p>
                <p>Accordingly, the evolution of the infection is given by the following set of equations
<disp-formula id="pone.0260364.e006"><alternatives><graphic xlink:href="pone.0260364.e006.jpg" id="pone.0260364.e006g" position="anchor"/><mml:math id="M6" display="block" overflow="scroll"><mml:mrow><mml:msub><mml:mi>S</mml:mi><mml:mrow><mml:mi>t</mml:mi><mml:mo>+</mml:mo><mml:mn>1</mml:mn></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:msub><mml:mi>S</mml:mi><mml:mi>t</mml:mi></mml:msub><mml:mo>−</mml:mo><mml:msub><mml:mi>β</mml:mi><mml:mi>t</mml:mi></mml:msub><mml:msub><mml:mi>S</mml:mi><mml:mi>t</mml:mi></mml:msub><mml:msub><mml:mi>I</mml:mi><mml:mi>t</mml:mi></mml:msub><mml:mo>/</mml:mo><mml:mi>N</mml:mi><mml:mo>,</mml:mo></mml:mrow></mml:math></alternatives><label>(3)</label></disp-formula>
<disp-formula id="pone.0260364.e007"><alternatives><graphic xlink:href="pone.0260364.e007.jpg" id="pone.0260364.e007g" position="anchor"/><mml:math id="M7" display="block" overflow="scroll"><mml:mrow><mml:msub><mml:mi>E</mml:mi><mml:mrow><mml:mi>t</mml:mi><mml:mo>+</mml:mo><mml:mn>1</mml:mn></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mn>1</mml:mn><mml:mo>−</mml:mo><mml:mi>α</mml:mi></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:msub><mml:mi>E</mml:mi><mml:mi>t</mml:mi></mml:msub><mml:mo>+</mml:mo><mml:msub><mml:mi>β</mml:mi><mml:mi>t</mml:mi></mml:msub><mml:msub><mml:mi>S</mml:mi><mml:mi>t</mml:mi></mml:msub><mml:msub><mml:mi>I</mml:mi><mml:mi>t</mml:mi></mml:msub><mml:mo>/</mml:mo><mml:mi>N</mml:mi><mml:mo>,</mml:mo></mml:mrow></mml:math></alternatives><label>(4)</label></disp-formula>
<disp-formula id="pone.0260364.e008"><alternatives><graphic xlink:href="pone.0260364.e008.jpg" id="pone.0260364.e008g" position="anchor"/><mml:math id="M8" display="block" overflow="scroll"><mml:mrow><mml:msubsup><mml:mi>I</mml:mi><mml:mrow><mml:mi>t</mml:mi><mml:mo>+</mml:mo><mml:mn>1</mml:mn></mml:mrow><mml:mi>C</mml:mi></mml:msubsup><mml:mo>=</mml:mo><mml:mi>ρ</mml:mi><mml:mi>α</mml:mi><mml:msub><mml:mi>E</mml:mi><mml:mi>t</mml:mi></mml:msub><mml:mo>+</mml:mo><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mn>1</mml:mn><mml:mo>−</mml:mo><mml:mi>γ</mml:mi></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:msubsup><mml:mi>I</mml:mi><mml:mi>t</mml:mi><mml:mi>C</mml:mi></mml:msubsup><mml:mo>,</mml:mo></mml:mrow></mml:math></alternatives><label>(5)</label></disp-formula>
<disp-formula id="pone.0260364.e009"><alternatives><graphic xlink:href="pone.0260364.e009.jpg" id="pone.0260364.e009g" position="anchor"/><mml:math id="M9" display="block" overflow="scroll"><mml:mrow><mml:msubsup><mml:mi>I</mml:mi><mml:mrow><mml:mi>t</mml:mi><mml:mo>+</mml:mo><mml:mn>1</mml:mn></mml:mrow><mml:mrow><mml:mi>S</mml:mi><mml:mi>C</mml:mi></mml:mrow></mml:msubsup><mml:mo>=</mml:mo><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mn>1</mml:mn><mml:mo>−</mml:mo><mml:mi>ρ</mml:mi></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:mi>α</mml:mi><mml:msub><mml:mi>E</mml:mi><mml:mi>t</mml:mi></mml:msub><mml:mo>+</mml:mo><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mn>1</mml:mn><mml:mo>−</mml:mo><mml:mi>γ</mml:mi></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:msubsup><mml:mi>I</mml:mi><mml:mi>t</mml:mi><mml:mrow><mml:mi>S</mml:mi><mml:mi>C</mml:mi></mml:mrow></mml:msubsup></mml:mrow></mml:math></alternatives><label>(6)</label></disp-formula>
<disp-formula id="pone.0260364.e010"><alternatives><graphic xlink:href="pone.0260364.e010.jpg" id="pone.0260364.e010g" position="anchor"/><mml:math id="M10" display="block" overflow="scroll"><mml:mrow><mml:msub><mml:mi>R</mml:mi><mml:mrow><mml:mi>t</mml:mi><mml:mo>+</mml:mo><mml:mn>1</mml:mn></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:msub><mml:mi>R</mml:mi><mml:mi>t</mml:mi></mml:msub><mml:mo>+</mml:mo><mml:mi>γ</mml:mi><mml:msub><mml:mi>I</mml:mi><mml:mi>t</mml:mi></mml:msub><mml:mo>,</mml:mo></mml:mrow></mml:math></alternatives><label>(7)</label></disp-formula>
with <inline-formula id="pone.0260364.e011"><alternatives><graphic xlink:href="pone.0260364.e011.jpg" id="pone.0260364.e011g" position="anchor"/><mml:math id="M11" display="inline" overflow="scroll"><mml:mrow><mml:msub><mml:mi>I</mml:mi><mml:mi>t</mml:mi></mml:msub><mml:mo>=</mml:mo><mml:msubsup><mml:mi>I</mml:mi><mml:mi>t</mml:mi><mml:mi>C</mml:mi></mml:msubsup><mml:mo>+</mml:mo><mml:msubsup><mml:mi>I</mml:mi><mml:mi>t</mml:mi><mml:mrow><mml:mi>S</mml:mi><mml:mi>C</mml:mi></mml:mrow></mml:msubsup></mml:mrow></mml:math></alternatives></inline-formula>, where <italic toggle="yes">β</italic><sub><italic toggle="yes">t</italic></sub> captures the daily transmission rate of COVID-19 (as above), <italic toggle="yes">α</italic> is the parameter related to the incubation with 1/<italic toggle="yes">α</italic> being the average incubation period (in days) and <italic toggle="yes">γ</italic> is the daily probability that an infected individual becomes removed (as above). Note that the confirmed daily cases <italic toggle="yes">c</italic><sub><italic toggle="yes">t</italic></sub> refer to only the symptomatic, which means that <italic toggle="yes">c</italic><sub><italic toggle="yes">t</italic></sub> = <italic toggle="yes">ραE</italic><sub><italic toggle="yes">t</italic>-1</sub>. hence <xref rid="pone.0260364.e002" ref-type="disp-formula">Eq (1)</xref> can be expressed as
<disp-formula id="pone.0260364.e012"><alternatives><graphic xlink:href="pone.0260364.e012.jpg" id="pone.0260364.e012g" position="anchor"/><mml:math id="M12" display="block" overflow="scroll"><mml:mrow><mml:msub><mml:mi>β</mml:mi><mml:mi>t</mml:mi></mml:msub><mml:mo>=</mml:mo><mml:mi>ζ</mml:mi><mml:mi>ρ</mml:mi><mml:mi>α</mml:mi><mml:msub><mml:mi>E</mml:mi><mml:mrow><mml:mi>t</mml:mi><mml:mo>−</mml:mo><mml:mn>2</mml:mn></mml:mrow></mml:msub><mml:mo>+</mml:mo><mml:mi>ε</mml:mi></mml:mrow></mml:math></alternatives><label>(8)</label></disp-formula>
We note that intuitively <italic toggle="yes">ζ</italic> should be negative such that an increase in confirmed cases leads to an increase in physical distancing practices, hence to a reduction in <italic toggle="yes">β</italic><sub><italic toggle="yes">t</italic>.</sub></p>
                <p>Eqs (<xref rid="pone.0260364.e003" ref-type="disp-formula">2</xref>)–(<xref rid="pone.0260364.e012" ref-type="disp-formula">8</xref>) constitute the baseline Behavioural SEIR (BeSEIR) model based on UK data. The last equation captures the behavioural part of the compartmental model based in the UK and may differ for other countries or other epidemics as the linear relationship which we observed may not hold in other jurisdictions or countries.</p>
              </sec>
            </sec>
            <sec sec-type="conclusions" id="sec005">
              <title>Results and discussion</title>
              <sec sec-type="results" id="sec006">
                <title>Results</title>
                <p>We simulated the contagion dynamics in the UK and the different effects of policies over two periods of 200 and 300 days, respectively, with the demographic changes being ignored, hence keeping the total number of individuals as constant. For Eqs (<xref rid="pone.0260364.e006" ref-type="disp-formula">3</xref>)–(<xref rid="pone.0260364.e010" ref-type="disp-formula">7</xref>), we used values from relevant published works. We used the data from a counterfactual SEIR model with <italic toggle="yes">β</italic> = <italic toggle="yes">β</italic><sub>0</sub>, <italic toggle="yes">γ</italic> = 0.133, <italic toggle="yes">ρ</italic> = 0.4 (Prem et al. 2020) [<xref rid="pone.0260364.ref008" ref-type="bibr">8</xref>], Ν = 50000000 (roughly the number of adults in the UK [<xref rid="pone.0260364.ref019" ref-type="bibr">19</xref>], and started with 1000 people exposed at t = 0. We started our simulations with a seed of 1000 people exposed on Day 0. Genetic analysis has showed 1356 transmission lineages of COVID-19 in the UK [<xref rid="pone.0260364.ref020" ref-type="bibr">20</xref>].</p>
                <p>We calibrated the constants of <xref rid="pone.0260364.e012" ref-type="disp-formula">Eq (8)</xref> as follows:</p>
                <p>For <italic toggle="yes">E</italic><sub><italic toggle="yes">t</italic>-2</sub> = 0, we get <italic toggle="yes">β</italic><sub>0</sub> = <italic toggle="yes">ε</italic>. <xref rid="pone.0260364.e002" ref-type="disp-formula">Eq (1)</xref> can be expressed as <italic toggle="yes">R</italic><sub>0</sub><italic toggle="yes">γ</italic> = <italic toggle="yes">Pm</italic><sub>0</sub>, which means that for <italic toggle="yes">m</italic><sub>0</sub> = 1 (equivalent to 100% mobility levels) and given values of <italic toggle="yes">γ</italic> and <italic toggle="yes">R</italic><sub>0</sub> we can find <italic toggle="yes">P</italic> and <italic toggle="yes">β</italic><sub><italic toggle="yes">A</italic></sub>, the value of the reproduction number at the time when the NPIs are introduced.</p>
                <p>From Flaxman et al. (2020) [<xref rid="pone.0260364.ref012" ref-type="bibr">12</xref>], we set <italic toggle="yes">R</italic><sub>0</sub> = 3.8, which gives <italic toggle="yes">β</italic><sub>0</sub> = <italic toggle="yes">ε</italic> = <italic toggle="yes">R</italic><sub>0</sub><italic toggle="yes">γ</italic> = 0.5. We observed that the UK government started implementing measures when new cases per day were 409 [<xref rid="pone.0260364.ref001" ref-type="bibr">1</xref>]. Using the counterfactual BeSEIR model, we chose the time step with the closest value, which was 441 on day 24. Hence, for <italic toggle="yes">ρ</italic><italic toggle="yes">αE</italic><sub><italic toggle="yes">t</italic>-2</sub> = 441, <italic toggle="yes">β</italic><sub><italic toggle="yes">A</italic></sub> = 441<italic toggle="yes">ζ</italic> + <italic toggle="yes">β</italic><sub>0</sub></p>
                <p>which gives <italic toggle="yes">ζ</italic> = (<italic toggle="yes">β</italic><sub><italic toggle="yes">A</italic></sub>− <italic toggle="yes">β</italic><sub>0</sub>)/409 = -0.00016.</p>
                <p>We then considered the peak in new clinical cases per day as the time of the maximum physical distancing and <italic toggle="yes">m</italic><sub><italic toggle="yes">t</italic></sub> = 0.2 and thus the lowest value of the effective reproduction number. Based on this we calculated the value of <italic toggle="yes">β</italic><sub><italic toggle="yes">t</italic></sub> on that day (at t = 104), which we call <italic toggle="yes">β</italic><sub><italic toggle="yes">B</italic></sub> and is 0.10. Using this value, we calculated the parameters of <xref rid="pone.0260364.e012" ref-type="disp-formula">Eq (8)</xref> after the measures. Call these parameters <italic toggle="yes">ζ</italic><italic toggle="yes">’</italic> = -0.0001734341 and <italic toggle="yes">ε’</italic> = 0.1769653. Using these values, our extended BeSEIR model was able to reproduce the dynamics of contagion in the UK (<xref rid="pone.0260364.g002" ref-type="fig">Fig 2A and 2B</xref>).</p>
                <fig position="float" id="pone.0260364.g002">
                  <object-id pub-id-type="doi">10.1371/journal.pone.0260364.g002</object-id>
                  <label>Fig 2</label>
                  <caption>
                    <title>Behavioural SEIR model simulation for the UK adult population, with measures implemented on Day 24, when the number of new observable cases per day is similar to what was in the UK on 16-03-2020.</title>
                    <p>Panel A shows the percentage of Exposed and Infected (both clinical and sub-clinical) individuals per day. Panel B shows the reproduction number of the disease (Rt) over time. Panel C shows the cumulative infected people as predicted with the standard SEIR model–blue line vs the BeSEIR model–red line. Panel D shows the infected people at any time point as predicted by the standard SEIR. Panel E shows the infected people at any time point as predicted by the behavioural SEIR. <italic toggle="yes">R</italic><sub>0</sub> = 3.8, α = 0.15625, γ = 0.1331221, starting seed = 1000 individuals exposed on Day 0.</p>
                  </caption>
                  <graphic xlink:href="pone.0260364.g002" position="float"/>
                </fig>
                <p>We compared the simulation results of our model with a standard SEIR model and found that the latter model predicts a number of infections both cumulative (<xref rid="pone.0260364.g002" ref-type="fig">Fig 2C</xref>) and per day, much higher than the BeSEIR (<xref rid="pone.0260364.g002" ref-type="fig">Fig 2D and 2E</xref>). The difference regarding infections is several orders of magnitude, which highlights the importance of taking into account behavioural factors.</p>
                <p>We compared the effectiveness of NPIs between our model and the standard SEIR. As expected in the standard SEIR, the cumulative number of infected individuals is lower than in the BeSEIR (<xref rid="pone.0260364.g003" ref-type="fig">Fig 3A</xref>). As in the previous case, the cumulative number differs by several orders of magnitude. We noticed that the reproduction number on the standard SEIR is only affected by NPIs (<xref rid="pone.0260364.g003" ref-type="fig">Fig 3B</xref>).</p>
                <fig position="float" id="pone.0260364.g003">
                  <object-id pub-id-type="doi">10.1371/journal.pone.0260364.g003</object-id>
                  <label>Fig 3</label>
                  <caption>
                    <title>BeSEIR vs standard SEIR with NPIs implemented on Day 24.</title>
                    <p>Panel A shows the cumulative infected people as predicted with the standard SEIR model–blue line vs the behavioural SEIR model–red line. Panel B shows the reproduction number over time. Panel C shows the infected people at any time point as predicted by the standard SEIR. Panel D shows the infected people at any time point as predicted by the behavioural SEIR.</p>
                  </caption>
                  <graphic xlink:href="pone.0260364.g003" position="float"/>
                </fig>
                <p>We tested the impact on the total number of infected individuals and the maximum confirmed daily cases of the delay of (i) implementing the measures (ii) and lifting restrictions. This allowed us to compute the cost in terms of lockdown days in order to reach the same reproduction number. The next graph shows the dynamics of key variables compared to a hypothetical situation when the same measures had been taken 7 days earlier than the actual date of intervention.</p>
                <p>We noticed that, while the timing of measures has an important impact on the number of infected individuals (both daily and cumulatively, <xref rid="pone.0260364.g004" ref-type="fig">Fig 4A–4C</xref>), the reproduction number is reduced relatively less compared to the scenario where the measures are taken later (<xref rid="pone.0260364.g004" ref-type="fig">Fig 4D</xref>). This highlights that all other factors being equal, it may be optimal to have a relatively higher reproduction number with a lower number of infected rather than the opposite. This is due to the fact that the number of infected individuals at any point in time depends both in the reproduction number and the number of infected in the previous period. Hence a later intervention would require a higher reduction in the reproduction number to have the same reduction in infections to an earlier one.</p>
                <fig position="float" id="pone.0260364.g004">
                  <object-id pub-id-type="doi">10.1371/journal.pone.0260364.g004</object-id>
                  <label>Fig 4</label>
                  <caption>
                    <title>BeSEIR model comparing the effect of measures taken on Day 24, baseline model–red line or measures taken on Day 17, early model–blue line.</title>
                    <p>A: Percentage of infected individuals. B: Percentage of Removed individuals. C: Percentage of Exposed individuals. D: Reproduction number <italic toggle="yes">R</italic><sub><italic toggle="yes">e</italic></sub> = <italic toggle="yes">β</italic><sub><italic toggle="yes">t</italic></sub>/<italic toggle="yes">γ</italic>.</p>
                  </caption>
                  <graphic xlink:href="pone.0260364.g004" position="float"/>
                </fig>
                <p>Interestingly, we noticed that the maximum number of infected individuals at any point in time using the BeSEIR model is significantly and much more realistically lower than the standard SEIR (<xref rid="pone.0260364.g004" ref-type="fig">Fig 4C and 4D</xref>), where it also takes longer for the number of infected to be reduced.</p>
                <p>We tested the impact of lifting the measures earlier rather than later and also compared this to the hypothetical case of earlier timing of NPIs. As expected, the most efficient policy would be to both delay lifting physical distancing measures and implementing NPIs early (<xref rid="pone.0260364.g005" ref-type="fig">Fig 5</xref>). We noticed that taking the timing regarding on when the measures are lifted plays a less important role (assuming that there will be a lift) compared to the timing of imposing the measures.</p>
                <fig position="float" id="pone.0260364.g005">
                  <object-id pub-id-type="doi">10.1371/journal.pone.0260364.g005</object-id>
                  <label>Fig 5</label>
                  <caption>
                    <title>BeSEIR model comparing the effect of measures taken on Day 24 and lifted on Day 114, baseline model–red line, measures taken on Day 17 and lifted on Day 114, early model–green line, or measures taken on Day 17 and lifted on Day 107, early model and early lifting–blue line.</title>
                    <p>A: Percentage of infected individuals. B: Percentage of Removed individuals. C: Percentage of Exposed individuals. D: Reproduction number <italic toggle="yes">R</italic><sub><italic toggle="yes">e</italic></sub> = <italic toggle="yes">β</italic><sub><italic toggle="yes">t</italic></sub>/<italic toggle="yes">γ</italic>.</p>
                  </caption>
                  <graphic xlink:href="pone.0260364.g005" position="float"/>
                </fig>
              </sec>
            </sec>
            <sec sec-type="conclusions" id="sec007">
              <title>Discussion</title>
              <p>In this paper argued that in order to be able to evaluate the effectiveness of NPIs, it is necessary to explicitly take account of the behavioural change with regards to physical distancing due to both the relevant NPIs and independent individual choices. If the behaviour of individuals is not taken into account, the levels of physical distancing without measures can be underestimated and similarly the effectiveness of measures can be overestimated. Hence, incorporating an autonomous element of physical distancing can also increase the accuracy of modelling predictions.</p>
              <p>Using aggregate mobility data for the UK, we observed that individual mobility levels had been reducing before the measures were taken and have been increasing even before the announcement of relaxation of the measures. We tested whether information regarding confirmed cases can explain the changes in mobility within the different periods of NPIs. In order to also take into consideration, the effects of policies, we considered three distinct periods: before advice, between advice and lockdown, and after lockdown. We found high correlation in all three periods, which confirms the fact that people have been making physical distancing choices using the available information regarding the number of cases which are also assumed to be correlated to the number of deaths. We note that the number of cases reported, at the early phases of the epidemic at least, was a gross underestimate of the real cases. However, the number of deaths has been used in order to infer the number of cases by imposing a somewhat arbitrary death rate. Given this as long as the number of deaths is a fraction of the number of cases the outcome of our BeSEIR model will not change and in addition we acknowledge that people make decisions based on imperfect information.</p>
              <p>Our results not only confirm that individual behaviour should be taken into account but also provides a functional form that can be used in models which have similar assumptions regarding physical distancing behaviour [<xref rid="pone.0260364.ref006" ref-type="bibr">6</xref>, <xref rid="pone.0260364.ref007" ref-type="bibr">7</xref>, <xref rid="pone.0260364.ref015" ref-type="bibr">15</xref>]. Other studies modelling the COVID-19 pandemic taking into account government interventions implicitly assume a behavioral change as a function of NPIs [<xref rid="pone.0260364.ref021" ref-type="bibr">21</xref>–<xref rid="pone.0260364.ref023" ref-type="bibr">23</xref>], whereas our study links the behavioral component to the available information and the current state of the progression of the pandemic. Furthermore, this type of empirical exercise can be replicated across countries to analyse the relative role of social and economic conditions in physical distancing practices along the lines discussed in [<xref rid="pone.0260364.ref013" ref-type="bibr">13</xref>, <xref rid="pone.0260364.ref014" ref-type="bibr">14</xref>].</p>
              <p>This observation raised two policy related questions with regards to the timing of making the interventions and the time of lifting these. Given that individuals react autonomously, policies are less effective compared to a situation where individuals do not act independently. However, it is not clear how much this behaviour would impact the overall results.</p>
              <p>We showed that when the level of daily infections is relatively low, more strict measures are required in order to achieve high levels of physical distancing. This means that the same level of measures may be less effective in reducing the reproduction number if these are imposed earlier rather than later. But importantly, this does not mean that early measures are less effective in reducing the overall number of infections. NPIs which are imposed even a week earlier can have an important impact in the reduction of infections.</p>
              <p>This finding may give an explanation about the initial spread of the epidemic in countries that were hit first. Given the high uncertainty and the much lower volumes of information the endogenous behavioural component we describe couldn’t have a significant effect in these countries. On the other hand, quickly introduced NPIs in the form of enforceable lockdowns were the only way to reduce the spread of the epidemic.</p>
            </sec>
            <sec sec-type="conclusions" id="sec008">
              <title>Conclusion</title>
              <p>In order to be able to assess the effects of the different policies, we first extended the standard SEIR model to a BeSEIR one and calibrated it using epidemiological data from previous relevant studies. Our results highlight two issues. First, not taking into account the fact that individuals also react themselves over and above NPIs may lead to very misleading projections with regards to the effectiveness of measures. Second, the fact that even though the reproduction number is a relevant variable for policy purposes, it is not necessarily a measure of success of NPIs. A higher reproduction number with less active cases can be preferable to the opposite can be less challenging to the capacity of a given health system. Of course, the basic reproduction number of the disease as defined by the biological features of the SARS-COV-2 virus is still important as it is predictive of the epidemic curve in the absence of NPIs or changes in human behaviour.</p>
              <disp-formula id="pone.0260364.e013">
                <alternatives>
                  <graphic xlink:href="pone.0260364.e013.jpg" id="pone.0260364.e013g" position="anchor"/>
                  <mml:math id="M13" display="block" overflow="scroll">
                    <mml:mrow>
                      <mml:msub>
                        <mml:mi>R</mml:mi>
                        <mml:mn>0</mml:mn>
                      </mml:msub>
                      <mml:msub>
                        <mml:mi>R</mml:mi>
                        <mml:mi>e</mml:mi>
                      </mml:msub>
                      <mml:mo>=</mml:mo>
                      <mml:msub>
                        <mml:mi>β</mml:mi>
                        <mml:mi>t</mml:mi>
                      </mml:msub>
                      <mml:mtext>/</mml:mtext>
                      <mml:mi>γ</mml:mi>
                      <mml:msub>
                        <mml:mi>R</mml:mi>
                        <mml:mi>e</mml:mi>
                      </mml:msub>
                      <mml:mo>=</mml:mo>
                      <mml:msub>
                        <mml:mi>β</mml:mi>
                        <mml:mi>t</mml:mi>
                      </mml:msub>
                      <mml:mtext>/</mml:mtext>
                      <mml:mi>γ</mml:mi>
                    </mml:mrow>
                  </mml:math>
                </alternatives>
              </disp-formula>
            </sec>
            <sec id="sec009" sec-type="supplementary-material">
              <title>Supporting information</title>
              <supplementary-material id="pone.0260364.s001" position="float" content-type="local-data">
                <label>S1 Fig</label>
                <caption>
                  <title>Scatterplots showing the relationship between the mobility percentage drop from baseline and the logit transformation of new COVID-19 cases per day in the UK.</title>
                  <p>A regression line is drawn in black with the corresponding 95% confidence interval in grey. We also show the Pearson’s correlation coefficient—"R" and the corresponding p.value—"p" assessing the significance of the correlation coefficient estimate. A: The relationship before the advice for maintaining physical distancing. B: The relationship after the advice for physical distancing but before enforceable lockdown. C: The relationship after lockdown.</p>
                  <p>(TIF)</p>
                </caption>
                <media xlink:href="pone.0260364.s001.tif">
                  <caption>
                    <p>Click here for additional data file.</p>
                  </caption>
                </media>
              </supplementary-material>
            </sec>
          </body>
          <back>
            <ref-list>
              <title>References</title>
              <ref id="pone.0260364.ref001">
                <label>1</label>
                <mixed-citation publication-type="other">WHO Coronavirus Disease (COVID-19) Dashboard [Internet]. [cited 2020 Jun 25]. Available from: <ext-link xlink:href="https://covid19.who.int/?gclid=CjwKCAjwltH3BRB6EiwAhj0IUD_ZYpmWYI5f1P9OYsYlJKTajlyFvk5aXAwQNMNIoL82XsVMfF4LExoC8e4QAvD_BwE" ext-link-type="uri">https://covid19.who.int/?gclid=CjwKCAjwltH3BRB6EiwAhj0IUD_ZYpmWYI5f1P9OYsYlJKTajlyFvk5aXAwQNMNIoL82XsVMfF4LExoC8e4QAvD_BwE</ext-link></mixed-citation>
              </ref>
              <ref id="pone.0260364.ref002">
                <label>2</label>
                <mixed-citation publication-type="journal"><name><surname>Ahmed</surname><given-names>F</given-names></name>, <name><surname>Ahmed</surname><given-names>N</given-names></name>, <name><surname>Pissarides</surname><given-names>C</given-names></name>, <name><surname>Stiglitz</surname><given-names>J</given-names></name>. <article-title>Why inequality could spread COVID-19</article-title>. <source>Lancet Public Health</source>. <year>2020</year>;<volume>5</volume>(<issue>5</issue>):<fpage>e240</fpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1016/S2468-2667(20)30085-2</pub-id><?supplied-pmid 32247329?><pub-id pub-id-type="pmid">32247329</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0260364.ref003">
                <label>3</label>
                <mixed-citation publication-type="journal"><name><surname>Moore</surname><given-names>S</given-names></name>, <name><surname>Hill</surname><given-names>EM</given-names></name>, <name><surname>Tildesley</surname><given-names>MJ</given-names></name>, <name><surname>Dyson</surname><given-names>L</given-names></name>, <name><surname>Keeling</surname><given-names>MJ</given-names></name>. <article-title>Vaccination and non-pharmaceutical interventions for COVID-19: a mathematical modelling study</article-title>. <source>The Lancet Infectious Diseases</source>. <year>2021</year><month>Jun</month><day>1</day>;<volume>21</volume>(<issue>6</issue>):<fpage>793</fpage>–<lpage>802</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1016/S1473-3099(21)00143-2</pub-id>
<?supplied-pmid 33743847?><pub-id pub-id-type="pmid">33743847</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0260364.ref004">
                <label>4</label>
                <mixed-citation publication-type="journal"><name><surname>Betti</surname><given-names>M</given-names></name>, <name><surname>Bragazzi</surname><given-names>NL</given-names></name>, <name><surname>Heffernan</surname><given-names>JM</given-names></name>, <name><surname>Kong</surname><given-names>J</given-names></name>, <name><surname>Raad</surname><given-names>A</given-names></name>. <article-title>Integrated vaccination and non-pharmaceutical interventions based strategies in Ontario, Canada, as a case study: a mathematical modelling study</article-title>. <source>Journal of The Royal Society Interface</source>. <volume>18</volume>(<issue>180</issue>):<fpage>20210009</fpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1098/rsif.2021.0009</pub-id><?supplied-pmid 34255985?><pub-id pub-id-type="pmid">34255985</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0260364.ref005">
                <label>5</label>
                <mixed-citation publication-type="journal"><name><surname>Gozzi</surname><given-names>N</given-names></name>, <name><surname>Bajardi</surname><given-names>P</given-names></name>, <name><surname>Perra</surname><given-names>N</given-names></name>. <article-title>The importance of non-pharmaceutical interventions during the COVID-19 vaccine rollout</article-title>. <source>PLOS Computational Biology</source>. <year>2021</year><month>Sep</month><day>10</day>;<volume>17</volume>(<issue>9</issue>):<fpage>e1009346</fpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1371/journal.pcbi.1009346</pub-id><?supplied-pmid 34506478?><pub-id pub-id-type="pmid">34506478</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0260364.ref006">
                <label>6</label>
                <mixed-citation publication-type="journal"><name><surname>Di Guilmi</surname><given-names>C</given-names></name>, <name><surname>Galanis</surname><given-names>G</given-names></name>, <name><surname>Baskozos</surname><given-names>G</given-names></name>. <article-title>A Behavioural SIR Model and its Implications for Physical Distancing</article-title>. <source>Review of Behavioral Economics</source> [Internet]. <month>August</month> 20212;Forthcoming(2021–10–15). Available from: <ext-link xlink:href="http://hdl.handle.net/10453/150156" ext-link-type="uri">http://hdl.handle.net/10453/150156</ext-link></mixed-citation>
              </ref>
              <ref id="pone.0260364.ref007">
                <label>7</label>
                <mixed-citation publication-type="journal"><name><surname>Flaschel</surname><given-names>P</given-names></name>, <name><surname>Galanis</surname><given-names>G</given-names></name>, <name><surname>Tavani</surname><given-names>D</given-names></name>, <name><surname>Venezian</surname><given-names>R</given-names></name>. <source>Pandemics and aggregate demand: A framework for policy analysis</source> [Internet]. Centre for Applied Macroeconomic Analysis. The Australian National University; [cited 2021 Sep 23]. Available from: <ext-link xlink:href="https://cama.crawford.anu.edu.au/publication/cama-working-paper-series/18348/pandemics-and-aggregate-demand-framework-policy-analysis" ext-link-type="uri">https://cama.crawford.anu.edu.au/publication/cama-working-paper-series/18348/pandemics-and-aggregate-demand-framework-policy-analysis</ext-link></mixed-citation>
              </ref>
              <ref id="pone.0260364.ref008">
                <label>8</label>
                <mixed-citation publication-type="journal"><name><surname>Prem</surname><given-names>K</given-names></name>, <name><surname>Liu</surname><given-names>Y</given-names></name>, <name><surname>Russell</surname><given-names>TW</given-names></name>, <name><surname>Kucharski</surname><given-names>AJ</given-names></name>, <name><surname>Eggo</surname><given-names>RM</given-names></name>, <name><surname>Davies</surname><given-names>N</given-names></name>, <etal>et al</etal>. <article-title>The effect of control strategies to reduce social mixing on outcomes of the COVID-19 epidemic in Wuhan, China: a modelling study</article-title>. <source>Lancet Public Health</source>. <year>2020</year><month>May</month>;<volume>5</volume>(<issue>5</issue>):<fpage>e261</fpage>–<lpage>70</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1016/S2468-2667(20)30073-6</pub-id>
<?supplied-pmid 32220655?><pub-id pub-id-type="pmid">32220655</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0260364.ref009">
                <label>9</label>
                <mixed-citation publication-type="journal"><name><surname>Kissler</surname><given-names>SM</given-names></name>, <name><surname>Tedijanto</surname><given-names>C</given-names></name>, <name><surname>Goldstein</surname><given-names>E</given-names></name>, <name><surname>Grad</surname><given-names>YH</given-names></name>, <name><surname>Lipsitch</surname><given-names>M</given-names></name>. <article-title>Projecting the transmission dynamics of SARS-CoV-2 through the postpandemic period</article-title>. <source>Science</source>. <year>2020</year><month>May</month><day>22</day>;<volume>368</volume>(<issue>6493</issue>):<fpage>860</fpage>–<lpage>8</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1126/science.abb5793</pub-id>
<?supplied-pmid 32291278?><pub-id pub-id-type="pmid">32291278</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0260364.ref010">
                <label>10</label>
                <mixed-citation publication-type="journal"><name><surname>Anderson</surname><given-names>RM</given-names></name>, <name><surname>Heesterbeek</surname><given-names>H</given-names></name>, <name><surname>Klinkenberg</surname><given-names>D</given-names></name>, <name><surname>Hollingsworth</surname><given-names>TD</given-names></name>. <article-title>How will country-based mitigation measures influence the course of the COVID-19 epidemic?</article-title><source>Lancet</source>. <year>2020</year><month>Mar</month><day>21</day>;<volume>395</volume>(<issue>10228</issue>):<fpage>931</fpage>–<lpage>4</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1016/S0140-6736(20)30567-5</pub-id>
<?supplied-pmid 32164834?><pub-id pub-id-type="pmid">32164834</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0260364.ref011">
                <label>11</label>
                <mixed-citation publication-type="journal"><name><surname>Ferguson</surname><given-names>N</given-names></name>, <name><surname>Laydon</surname><given-names>D</given-names></name>, <name><surname>Nedjati Gilani</surname><given-names>G</given-names></name>, <name><surname>Imai</surname><given-names>N</given-names></name>, <name><surname>Ainslie</surname><given-names>K</given-names></name>, <name><surname>Baguelin</surname><given-names>M</given-names></name>, <etal>et al</etal>. <source>Report 9: Impact of non-pharmaceutical interventions (NPIs) to reduce COVID19 mortality and healthcare demand</source> [Internet]. 20. <year>2020</year>
<month>Mar</month> [cited 2020 Apr 14]. Available from: <ext-link xlink:href="http://spiral.imperial.ac.uk/handle/10044/1/77482" ext-link-type="uri">http://spiral.imperial.ac.uk/handle/10044/1/77482</ext-link></mixed-citation>
              </ref>
              <ref id="pone.0260364.ref012">
                <label>12</label>
                <mixed-citation publication-type="journal"><name><surname>Flaxman</surname><given-names>S</given-names></name>, <name><surname>Mishra</surname><given-names>S</given-names></name>, <name><surname>Gandy</surname><given-names>A</given-names></name>, <name><surname>Unwin</surname><given-names>HJT</given-names></name>, <name><surname>Mellan</surname><given-names>TA</given-names></name>, <name><surname>Coupland</surname><given-names>H</given-names></name>, <etal>et al</etal>. <article-title>Estimating the effects of non-pharmaceutical interventions on COVID-19 in Europe</article-title>. <source>Nature</source>. <year>2020</year><month>Aug</month>;<volume>584</volume>(<issue>7820</issue>):<fpage>257</fpage>–<lpage>61</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1038/s41586-020-2405-7</pub-id>
<?supplied-pmid 32512579?><pub-id pub-id-type="pmid">32512579</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0260364.ref013">
                <label>13</label>
                <mixed-citation publication-type="journal"><name><surname>Galanis</surname><given-names>G</given-names></name>, <name><surname>Hanieh</surname><given-names>A</given-names></name>. <article-title>Incorporating Social Determinants of Health into Modelling of COVID-19 and other Infectious Diseases: A Baseline Socio-economic Compartmental Model</article-title>. <source>Soc Sci Med</source>. <year>2021</year><month>Apr</month>;<volume>274</volume>:<fpage>113794</fpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1016/j.socscimed.2021.113794</pub-id><?supplied-pmid 33662772?><pub-id pub-id-type="pmid">33662772</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0260364.ref014">
                <label>14</label>
                <mixed-citation publication-type="journal"><name><surname>Gouzoulis</surname><given-names>G</given-names></name>, <name><surname>Galanis</surname><given-names>G</given-names></name>. <article-title>The impact of financialisation on public health in times of COVID-19 and beyond</article-title>. <source>Sociology of Health &amp; Illness</source>. <year>2021</year>;<volume>43</volume>(<issue>6</issue>):<fpage>1328</fpage>–<lpage>34</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1111/1467-9566.13305</pub-id>
<?supplied-pmid 34117649?><pub-id pub-id-type="pmid">34117649</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0260364.ref015">
                <label>15</label>
                <mixed-citation publication-type="journal"><name><surname>Eksin</surname><given-names>C</given-names></name>, <name><surname>Paarporn</surname><given-names>K</given-names></name>, <name><surname>Weitz</surname><given-names>JS</given-names></name>. <article-title>Systematic biases in disease forecasting—The role of behavior change</article-title>. <source>Epidemics</source>. <year>2019</year><month>Jun</month>;<volume>27</volume>:<fpage>96</fpage>–<lpage>105</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1016/j.epidem.2019.02.004</pub-id>
<?supplied-pmid 30922858?><pub-id pub-id-type="pmid">30922858</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0260364.ref016">
                <label>16</label>
                <mixed-citation publication-type="journal"><name><surname>Buckee</surname><given-names>CO</given-names></name>, <name><surname>Balsari</surname><given-names>S</given-names></name>, <name><surname>Chan</surname><given-names>J</given-names></name>, <name><surname>Crosas</surname><given-names>M</given-names></name>, <name><surname>Dominici</surname><given-names>F</given-names></name>, <name><surname>Gasser</surname><given-names>U</given-names></name>, <etal>et al</etal>. <article-title>Aggregated mobility data could help fight COVID-19</article-title>. <source>Science</source>. <year>2020</year><month>Apr</month><day>10</day>;<volume>368</volume>(<issue>6487</issue>):<fpage>145</fpage>–<lpage>6</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1126/science.abb8021</pub-id>
<?supplied-pmid 32205458?><pub-id pub-id-type="pmid">32205458</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0260364.ref017">
                <label>17</label>
                <mixed-citation publication-type="other">COVID-19 Community Mobility Report [Internet]. COVID-19 Community Mobility Report. [cited 2020 Jun 25]. Available from: <ext-link xlink:href="https://www.google.com/covid19/mobility?hl=en" ext-link-type="uri">https://www.google.com/covid19/mobility?hl=en</ext-link></mixed-citation>
              </ref>
              <ref id="pone.0260364.ref018">
                <label>18</label>
                <mixed-citation publication-type="other">National Travel Survey [Internet]. GOV.UK. [cited 2020 Jun 25]. Available from: <ext-link xlink:href="https://www.gov.uk/government/collections/national-travel-survey-statistics" ext-link-type="uri">https://www.gov.uk/government/collections/national-travel-survey-statistics</ext-link></mixed-citation>
              </ref>
              <ref id="pone.0260364.ref019">
                <label>19</label>
                <mixed-citation publication-type="other">Projected UK adult population for 2018—Office for National Statistics [Internet]. [cited 2021 Sep 23]. Available from: <ext-link xlink:href="https://www.ons.gov.uk/aboutus/transparencyandgovernance/freedomofinformationfoi/projectedukadultpopulationfor2018" ext-link-type="uri">https://www.ons.gov.uk/aboutus/transparencyandgovernance/freedomofinformationfoi/projectedukadultpopulationfor2018</ext-link></mixed-citation>
              </ref>
              <ref id="pone.0260364.ref020">
                <label>20</label>
                <mixed-citation publication-type="journal"><name><surname>du Plessis</surname><given-names>L</given-names></name>, <name><surname>McCrone</surname><given-names>JT</given-names></name>, <name><surname>Zarebski</surname><given-names>AE</given-names></name>, <name><surname>Hill</surname><given-names>V</given-names></name>, <name><surname>Ruis</surname><given-names>C</given-names></name>, <name><surname>Gutierrez</surname><given-names>B</given-names></name>, <etal>et al</etal>. <article-title>Establishment and lineage dynamics of the SARS-CoV-2 epidemic in the UK</article-title>. <source>Science</source>. <year>2021</year><month>Feb</month><day>12</day>;<volume>371</volume>(<issue>6530</issue>):<fpage>708</fpage>–<lpage>12</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1126/science.abf2946</pub-id>
<?supplied-pmid 33419936?><pub-id pub-id-type="pmid">33419936</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0260364.ref021">
                <label>21</label>
                <mixed-citation publication-type="journal"><name><surname>Rodríguez</surname><given-names>J</given-names></name>, <name><surname>Patón</surname><given-names>M</given-names></name>, <name><surname>Uratani</surname><given-names>JM</given-names></name>, <name><surname>Acuña</surname><given-names>JM</given-names></name>. <article-title>Modelling the impact of interventions on the progress of the COVID-19 outbreak including age segregation</article-title>. <source>PLOS ONE</source>. <year>2021</year><month>Mar</month><day>15</day>;<volume>16</volume>(<issue>3</issue>):<fpage>e0248243</fpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1371/journal.pone.0248243</pub-id><?supplied-pmid 33720988?><pub-id pub-id-type="pmid">33720988</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0260364.ref022">
                <label>22</label>
                <mixed-citation publication-type="journal"><name><surname>Sharma</surname><given-names>M</given-names></name>, <name><surname>Mindermann</surname><given-names>S</given-names></name>, <name><surname>Rogers-Smith</surname><given-names>C</given-names></name>, <name><surname>Leech</surname><given-names>G</given-names></name>, <name><surname>Snodin</surname><given-names>B</given-names></name>, <name><surname>Ahuja</surname><given-names>J</given-names></name>, <etal>et al</etal>. <source>Understanding the effectiveness of government interventions in Europe’s second wave of COVID-19</source> [Internet]. <year>2021</year>
<month>Mar</month> [cited 2021 Sep 22] p. 2021.03.25.21254330. Available from: <ext-link xlink:href="https://www.medrxiv.org/content/10.1101/2021.03.25.21254330v1" ext-link-type="uri">https://www.medrxiv.org/content/10.1101/2021.03.25.21254330v1</ext-link></mixed-citation>
              </ref>
              <ref id="pone.0260364.ref023">
                <label>23</label>
                <mixed-citation publication-type="journal"><name><surname>Haug</surname><given-names>N</given-names></name>, <name><surname>Geyrhofer</surname><given-names>L</given-names></name>, <name><surname>Londei</surname><given-names>A</given-names></name>, <name><surname>Dervic</surname><given-names>E</given-names></name>, <name><surname>Desvars-Larrive</surname><given-names>A</given-names></name>, <name><surname>Loreto</surname><given-names>V</given-names></name>, <etal>et al</etal>. <article-title>Ranking the effectiveness of worldwide COVID-19 government interventions</article-title>. <source>Nat Hum Behav</source>. <year>2020</year><month>Dec</month>;<volume>4</volume>(<issue>12</issue>):<fpage>1303</fpage>–<lpage>12</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1038/s41562-020-01009-0</pub-id>
<?supplied-pmid 33199859?><pub-id pub-id-type="pmid">33199859</pub-id></mixed-citation>
              </ref>
            </ref-list>
          </back>
          <sub-article article-type="aggregated-review-documents" id="pone.0260364.r001" specific-use="decision-letter">
            <front-stub>
              <article-id pub-id-type="doi">10.1371/journal.pone.0260364.r001</article-id>
              <title-group>
                <article-title>Decision Letter 0</article-title>
              </title-group>
              <contrib-group>
                <contrib contrib-type="author">
                  <name>
                    <surname>Mitra</surname>
                    <given-names>Prasenjit</given-names>
                  </name>
                  <role>Academic Editor</role>
                </contrib>
              </contrib-group>
              <permissions>
                <copyright-statement>© 2021 Prasenjit Mitra</copyright-statement>
                <copyright-year>2021</copyright-year>
                <copyright-holder>Prasenjit Mitra</copyright-holder>
                <license>
                  <ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref>
                  <license-p>This is an open access article distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.</license-p>
                </license>
              </permissions>
              <related-article ext-link-type="doi" xlink:href="10.1371/journal.pone.0260364" id="rel-obj001" related-article-type="reviewed-article"/>
              <custom-meta-group>
                <custom-meta>
                  <meta-name>Submission Version</meta-name>
                  <meta-value>0</meta-value>
                </custom-meta>
              </custom-meta-group>
            </front-stub>
            <body>
              <p>
                <named-content content-type="letter-date">16 Sep 2021</named-content>
              </p>
              <p>PONE-D-21-13349The effectiveness of Non-Pharmaceutical Interventions in reducing the COVID-19 contagion in the UK, an observational and modelling study.PLOS ONE</p>
              <p>Dear Dr. Baskozos,</p>
              <p>Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.</p>
              <p>==============================</p>
              <p>ACADEMIC EDITOR: Please modify the manuscript==============================</p>
              <p>Please submit your revised manuscript by Oct 30 2021 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at <email>plosone@plos.org</email>. When you're ready to submit your revision, log on to <ext-link xlink:href="https://www.editorialmanager.com/pone/" ext-link-type="uri">https://www.editorialmanager.com/pone/</ext-link> and select the 'Submissions Needing Revision' folder to locate your manuscript file.</p>
              <p>Please include the following items when submitting your revised manuscript:<list list-type="bullet"><list-item><p>A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'.</p></list-item><list-item><p>A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'.</p></list-item><list-item><p>An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'.</p></list-item></list>If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter.</p>
              <p>If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: <ext-link xlink:href="https://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols" ext-link-type="uri">https://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols</ext-link>. Additionally, PLOS ONE offers an option for publishing peer-reviewed Lab Protocol articles, which describe protocols hosted on protocols.io. Read more information on sharing protocols at <ext-link xlink:href="https://plos.org/protocols?utm_medium=editorial-email&amp;utm_source=authorletters&amp;utm_campaign=protocols" ext-link-type="uri">https://plos.org/protocols?utm_medium=editorial-email&amp;utm_source=authorletters&amp;utm_campaign=protocols</ext-link>.</p>
              <p>We look forward to receiving your revised manuscript.</p>
              <p>Kind regards,</p>
              <p>Prasenjit Mitra, MD, CBiol, MRSB, MIScT, FLS, FACSc, FAACC</p>
              <p>Academic Editor</p>
              <p>PLOS ONE</p>
              <p>Journal Requirements:</p>
              <p>When submitting your revision, we need you to address these additional requirements.</p>
              <p>1.Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming. The PLOS ONE style templates can be found at</p>
              <p><ext-link xlink:href="https://journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf" ext-link-type="uri">https://journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf</ext-link> and <ext-link xlink:href="https://journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf" ext-link-type="uri">https://journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf</ext-link></p>
              <p>2. We note that the grant information you provided in the ‘Funding Information’ and ‘Financial Disclosure’ sections do not match.</p>
              <p>When you resubmit, please ensure that you provide the correct grant numbers for the awards you received for your study in the ‘Funding Information’ section.</p>
              <p>3. Please upload a copy of Supporting Information Figure 1 which you refer to in your text on page 4.</p>
              <p>4. Please review your reference list to ensure that it is complete and correct. If you have cited papers that have been retracted, please include the rationale for doing so in the manuscript text, or remove these references and replace them with relevant current references. Any changes to the reference list should be mentioned in the rebuttal letter that accompanies your revised manuscript. If you need to cite a retracted article, indicate the article’s retracted status in the References list and also include a citation and full reference for the retraction notice.</p>
              <p>[Note: HTML markup is below. Please do not edit.]</p>
              <p>Reviewers' comments:</p>
              <p>Reviewer's Responses to Questions</p>
              <p>
                <bold>Comments to the Author</bold>
              </p>
              <p>1. Is the manuscript technically sound, and do the data support the conclusions?</p>
              <p>The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented. </p>
              <p>Reviewer #1: Yes</p>
              <p>********** </p>
              <p>2. Has the statistical analysis been performed appropriately and rigorously? </p>
              <p>Reviewer #1: Yes</p>
              <p>********** </p>
              <p>3. Have the authors made all data underlying the findings in their manuscript fully available?</p>
              <p>The <ext-link xlink:href="http://www.plosone.org/static/policies.action#sharing" ext-link-type="uri">PLOS Data policy</ext-link> requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.</p>
              <p>Reviewer #1: Yes</p>
              <p>********** </p>
              <p>4. Is the manuscript presented in an intelligible fashion and written in standard English?</p>
              <p>PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.</p>
              <p>Reviewer #1: Yes</p>
              <p>********** </p>
              <p>5. Review Comments to the Author</p>
              <p>Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)</p>
              <p>Reviewer #1: The authors would need to revise the manuscript in line with the following;</p>
              <p>Introduction:</p>
              <p>The statement on the second paragraph may need to be revised to reflect the present day realities of availability of vaccines but with problems of vaccine hesitance.</p>
              <p>Methods:</p>
              <p>The authors may need to state how the data from Google’s “COVID-19 Community Mobility Reports were validated and abstracted.</p>
              <p>Discussion:</p>
              <p>The discussion section will need to revised from just discussing the findings of this study solely to brining into context findings of others studies</p>
              <p>Conclusion:</p>
              <p>The authors may consider summarising the conclusion as it is too lengthy in this present form</p>
              <p>********** </p>
              <p>6. PLOS authors have the option to publish the peer review history of their article (<ext-link xlink:href="https://journals.plos.org/plosone/s/editorial-and-peer-review-process#loc-peer-review-history" ext-link-type="uri">what does this mean?</ext-link>). If published, this will include your full peer review and any attached files.</p>
              <p>If you choose “no”, your identity will remain anonymous but your review may still be made public.</p>
              <p><bold>Do you want your identity to be public for this peer review?</bold> For information about this choice, including consent withdrawal, please see our <ext-link xlink:href="https://www.plos.org/privacy-policy" ext-link-type="uri">Privacy Policy</ext-link>.</p>
              <p>Reviewer #1: <bold>Yes: </bold>Tolulope Olumide Afolaranmi</p>
              <p>[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.]</p>
              <p>While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, <ext-link xlink:href="https://pacev2.apexcovantage.com/" ext-link-type="uri">https://pacev2.apexcovantage.com/</ext-link>. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at <email>figures@plos.org</email>. Please note that Supporting Information files do not need this step.</p>
            </body>
          </sub-article>
          <sub-article article-type="author-comment" id="pone.0260364.r002">
            <front-stub>
              <article-id pub-id-type="doi">10.1371/journal.pone.0260364.r002</article-id>
              <title-group>
                <article-title>Author response to Decision Letter 0</article-title>
              </title-group>
              <related-article ext-link-type="doi" xlink:href="10.1371/journal.pone.0260364" id="rel-obj002" related-article-type="editor-report"/>
              <custom-meta-group>
                <custom-meta>
                  <meta-name>Submission Version</meta-name>
                  <meta-value>1</meta-value>
                </custom-meta>
              </custom-meta-group>
            </front-stub>
            <body>
              <p>
                <named-content content-type="author-response-date">27 Sep 2021</named-content>
              </p>
              <p>Dear editors,</p>
              <p>Thank you for giving us the opportunity to submit a revised manuscript to PLOS One. Below is a detailed response to all the points raised by the reviewer. Our point by point response is in bold. In addition to the points discussed below we have edited the manuscript to be fully concordant with the formatting templates provided, amended the funding statement to reflect all funding sources, uploaded the missing “Supporting Information Figure 1” and reviewed our reference list. We thank the editor for providing constructive feedback on this issues. We have taken all their comments into account and we feel that they made the manuscript stronger.</p>
              <p>Yours sincerely, </p>
              <p> Georgios Baskozos</p>
              <p>Reviewer #1: The authors would need to revise the manuscript in line with the following;</p>
              <p>Introduction:</p>
              <p>The statement on the second paragraph may need to be revised to reflect the present day realities of availability of vaccines but with problems of vaccine hesitance.</p>
              <p>Thank you very much for this comment. The reviewer is right. We have changed this statement accordingly both in the introduction and the discussion.</p>
              <p>Methods:</p>
              <p>The authors may need to state how the data from Google’s “COVID-19 Community Mobility Reports were validated and abstracted.</p>
              <p>We have added a short paragraph when we present Google’s “COVID-19 Community Mobility Reports” where we discuss the expected range of values, anonymisation and data aggregation. We believe this additional information shows how data were validate to be within the expected range and provided full details on data collection and aggregation.</p>
              <p>Discussion:</p>
              <p>The discussion section will need to revised from just discussing the findings of this study solely to brining into context findings of others studies</p>
              <p>We have added a short paragraph which relates our work and results with other closely related studies and added the appropriate references. We have also moved part of our conclusion to the discussion section.</p>
              <p>Conclusion:</p>
              <p>The authors may consider summarising the conclusion as it is too lengthy in this present form</p>
              <p>We have significantly shortened the conclusion.</p>
              <supplementary-material id="pone.0260364.s002" position="float" content-type="local-data">
                <label>Attachment</label>
                <caption>
                  <p>Submitted filename: <named-content content-type="submitted-filename">Response to Reviewers.docx</named-content></p>
                </caption>
                <media xlink:href="pone.0260364.s002.docx">
                  <caption>
                    <p>Click here for additional data file.</p>
                  </caption>
                </media>
              </supplementary-material>
            </body>
          </sub-article>
          <sub-article article-type="aggregated-review-documents" id="pone.0260364.r003" specific-use="decision-letter">
            <front-stub>
              <article-id pub-id-type="doi">10.1371/journal.pone.0260364.r003</article-id>
              <title-group>
                <article-title>Decision Letter 1</article-title>
              </title-group>
              <contrib-group>
                <contrib contrib-type="author">
                  <name>
                    <surname>Mitra</surname>
                    <given-names>Prasenjit</given-names>
                  </name>
                  <role>Academic Editor</role>
                </contrib>
              </contrib-group>
              <permissions>
                <copyright-statement>© 2021 Prasenjit Mitra</copyright-statement>
                <copyright-year>2021</copyright-year>
                <copyright-holder>Prasenjit Mitra</copyright-holder>
                <license>
                  <ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref>
                  <license-p>This is an open access article distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.</license-p>
                </license>
              </permissions>
              <related-article ext-link-type="doi" xlink:href="10.1371/journal.pone.0260364" id="rel-obj003" related-article-type="reviewed-article"/>
              <custom-meta-group>
                <custom-meta>
                  <meta-name>Submission Version</meta-name>
                  <meta-value>1</meta-value>
                </custom-meta>
              </custom-meta-group>
            </front-stub>
            <body>
              <p>
                <named-content content-type="letter-date">9 Nov 2021</named-content>
              </p>
              <p>The effectiveness of Non-Pharmaceutical Interventions in reducing the COVID-19 contagion in the UK, an observational and modelling study.</p>
              <p>PONE-D-21-13349R1</p>
              <p>Dear Dr. Baskozos,</p>
              <p>We’re pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it meets all outstanding technical requirements.</p>
              <p>Within one week, you’ll receive an e-mail detailing the required amendments. When these have been addressed, you’ll receive a formal acceptance letter and your manuscript will be scheduled for publication.</p>
              <p>An invoice for payment will follow shortly after the formal acceptance. To ensure an efficient process, please log into Editorial Manager at <ext-link xlink:href="http://www.editorialmanager.com/pone/" ext-link-type="uri">http://www.editorialmanager.com/pone/</ext-link>, click the 'Update My Information' link at the top of the page, and double check that your user information is up-to-date. If you have any billing related questions, please contact our Author Billing department directly at <email>authorbilling@plos.org</email>.</p>
              <p>If your institution or institutions have a press office, please notify them about your upcoming paper to help maximize its impact. If they’ll be preparing press materials, please inform our press team as soon as possible -- no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact <email>onepress@plos.org</email>.</p>
              <p>Kind regards,</p>
              <p>Prasenjit Mitra, MD, CBiol, MRSB, MIScT, FLS, FACSc, FAACC</p>
              <p>Academic Editor</p>
              <p>PLOS ONE</p>
              <p>Additional Editor Comments (optional):</p>
              <p>Reviewers' comments:</p>
              <p>Reviewer's Responses to Questions</p>
              <p>
                <bold>Comments to the Author</bold>
              </p>
              <p>1. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the “Comments to the Author” section, enter your conflict of interest statement in the “Confidential to Editor” section, and submit your "Accept" recommendation.</p>
              <p>Reviewer #1: All comments have been addressed</p>
              <p>**********</p>
              <p>2. Is the manuscript technically sound, and do the data support the conclusions?</p>
              <p>The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented. </p>
              <p>Reviewer #1: Yes</p>
              <p>**********</p>
              <p>3. Has the statistical analysis been performed appropriately and rigorously? </p>
              <p>Reviewer #1: Yes</p>
              <p>**********</p>
              <p>4. Have the authors made all data underlying the findings in their manuscript fully available?</p>
              <p>The <ext-link xlink:href="http://www.plosone.org/static/policies.action#sharing" ext-link-type="uri">PLOS Data policy</ext-link> requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.</p>
              <p>Reviewer #1: Yes</p>
              <p>**********</p>
              <p>5. Is the manuscript presented in an intelligible fashion and written in standard English?</p>
              <p>PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.</p>
              <p>Reviewer #1: Yes</p>
              <p>**********</p>
              <p>6. Review Comments to the Author</p>
              <p>Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)</p>
              <p>Reviewer #1: The authors have addressed all the the review comments and the manuscript is now publication worthy.</p>
              <p>**********</p>
              <p>7. PLOS authors have the option to publish the peer review history of their article (<ext-link xlink:href="https://journals.plos.org/plosone/s/editorial-and-peer-review-process#loc-peer-review-history" ext-link-type="uri">what does this mean?</ext-link>). If published, this will include your full peer review and any attached files.</p>
              <p>If you choose “no”, your identity will remain anonymous but your review may still be made public.</p>
              <p><bold>Do you want your identity to be public for this peer review?</bold> For information about this choice, including consent withdrawal, please see our <ext-link xlink:href="https://www.plos.org/privacy-policy" ext-link-type="uri">Privacy Policy</ext-link>.</p>
              <p>Reviewer #1: <bold>Yes: </bold>Tolulope Olumide Afolaranmi</p>
            </body>
          </sub-article>
          <sub-article article-type="editor-report" id="pone.0260364.r004" specific-use="acceptance-letter">
            <front-stub>
              <article-id pub-id-type="doi">10.1371/journal.pone.0260364.r004</article-id>
              <title-group>
                <article-title>Acceptance letter</article-title>
              </title-group>
              <contrib-group>
                <contrib contrib-type="author">
                  <name>
                    <surname>Mitra</surname>
                    <given-names>Prasenjit</given-names>
                  </name>
                  <role>Academic Editor</role>
                </contrib>
              </contrib-group>
              <permissions>
                <copyright-statement>© 2021 Prasenjit Mitra</copyright-statement>
                <copyright-year>2021</copyright-year>
                <copyright-holder>Prasenjit Mitra</copyright-holder>
                <license>
                  <ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref>
                  <license-p>This is an open access article distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.</license-p>
                </license>
              </permissions>
              <related-article ext-link-type="doi" xlink:href="10.1371/journal.pone.0260364" id="rel-obj004" related-article-type="reviewed-article"/>
            </front-stub>
            <body>
              <p>
                <named-content content-type="letter-date">11 Nov 2021</named-content>
              </p>
              <p>PONE-D-21-13349R1 </p>
              <p>The effectiveness of Non-Pharmaceutical Interventions in reducing the COVID-19 contagion in the UK, an observational and modelling study. </p>
              <p>Dear Dr. Baskozos:</p>
              <p>I'm pleased to inform you that your manuscript has been deemed suitable for publication in PLOS ONE. Congratulations! Your manuscript is now with our production department. </p>
              <p>If your institution or institutions have a press office, please let them know about your upcoming paper now to help maximize its impact. If they'll be preparing press materials, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information please contact <email>onepress@plos.org</email>.</p>
              <p>If we can help with anything else, please email us at <email>plosone@plos.org</email>. </p>
              <p>Thank you for submitting your work to PLOS ONE and supporting open access. </p>
              <p>Kind regards, </p>
              <p>PLOS ONE Editorial Office Staff</p>
              <p>on behalf of</p>
              <p>Dr. Prasenjit Mitra </p>
              <p>Academic Editor</p>
              <p>PLOS ONE</p>
            </body>
          </sub-article>
        </article>
      </metadata>
    </record>
  </GetRecord>
</OAI-PMH>
